Destiny Pharma Announces Qualified Infectious Disease Product Designation Granted by US FDAfor XF-73 Dermal Gel for Treatment of Burn Wound Infections
Decision of the Board to Appoint Administrators
Destiny Pharma plc(“Destiny Pharma” or “the Company”) Decision of the Board of Directors to Appoint Administrators. Brighton, United Kingdom – 22 August 2024 – Destiny Pharma, a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and cure life threatening infections, today announces that further to the announcement of 15 July when it communicated its intention to delist and the subsequent […]
Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative Antibiotics in Cardio-vascular Surgery Patients.
Destiny Pharma initiates research to explore XF drug potential for CF
Destiny Pharma plc shares now trading on JP Jenkins
JP Jenkins LtdDestiny Pharma plc shares now trading on JP Jenkins 13-Aug-2024 / 07:00 GMT/BSTThe issuer is solely responsible for the content of this announcement. 13th Aug 2024 JPJ: DEST ISIN: GB00B60BD277 Destiny Pharma plc (“Destiny Pharma” or “the Company”) Shares now trading on JP Jenkins London, UK, 13th Aug 2024 – Destiny Pharma plc […]
Last Day of Dealings on AIM
Destiny Pharma plc(“Destiny Pharma” or “the Company”) Last Day of Dealings on AIM Brighton, United Kingdom ‐ 12 August 2024 ‐ Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and cure life‐threatening infections, reminds shareholders that the last day of trading in Destiny […]
Director/PDMR Shareholding
XF-73 prevents bacterial invasion of bloodstream
Result of GM and Cancellation of Trading on AIM
